Drug news

Orexo AB regains US marketing rights to Abstral

Read time: 1 mins

Last updated:6th Jun 2012

Published:6th Jun 2012

Source: Pharmawand

Orexo AB have regained from 1 January 2013 US rights to market Abstral (fentanyl citrate sublingual) from Kyowa Hakko Kirin/ProStraken. The emphasis in marketing in the US will now be on pain specialists and not oncologists. ProStraken is a company focused on oncology. Abstral will be followed in the US by OX 219, a treatment for opioid dependence. OX 219 is a sublingual formulation of already marketed buprenorphine/naloxone. Orexo hopes to file for OX 219 in the US in 2013. ProStraken will now have exclusive marketing rights to Abstral in Europe including the Nordic regions. Kyowa Hakko Kirin will continue to develop Abstral in Japan. Competitor in the US will be buccal Fentora from Cephalon.

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Click here to view

Related news and insights

Drug news

FDA approves high-concentration, citrate-free formulation of Cyltezo (adalimumab-adbm) injection, interchangeable biosimilar to Humira

Boehringer Ingelheim announced that the FDA has approved the high-concentration, citrate-free formulation of Cyltezo (adalimumab-adbm), the company’s interchangeable* biosimilar to Humira (adalimumab), to treat multiple chronic inflammatory diseases

1 mins

Drug news

FDA approval for Inceptiv closed-loop spinal cord stimulator stimulator (SCS)for the treatment of chronic pain

Medtronic plc announced that the FDA has approved the Inceptiv closed-loop rechargeable spinal cord stimulator (SCS) for the treatment of chronic pain

1 min

Drug news

The FDA has approved the Esprit BTK Everolimus Eluting Resorbable Scaffold System (Esprit BTK System), a breakthrough innovation for people with chronic limb-threatening ischemia below-the-knee

Abbott announced that the FDA has approved the Esprit BTK Everolimus Eluting Resorbable Scaffold System (Esprit BTK System), a breakthrough innovation for people with chronic limb-threatening ischemia (CLTI) below-the-knee (BTK)

2 min

See all news